A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study

ReAces is a novel puncturable transcatheter atrial septal defect occluder. The device success rate was 100% (n = 14 of 14) in the animal experiment. Four swine successfully received puncture of the device 60 days after implantation of the device. The acute procedure success rate in the 10 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaochun, Chen, Shasha, Li, Wei, Jilaihawi, Hasan, Piayda, Kerstin, Sievert, Horst, Zhou, Daxin, Pan, Wenzhi, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research - Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831856/
https://www.ncbi.nlm.nih.gov/pubmed/36644281
http://dx.doi.org/10.1016/j.jacbts.2022.06.010
_version_ 1784867937831616512
author Zhang, Xiaochun
Chen, Shasha
Li, Wei
Jilaihawi, Hasan
Piayda, Kerstin
Sievert, Horst
Zhou, Daxin
Pan, Wenzhi
Ge, Junbo
author_facet Zhang, Xiaochun
Chen, Shasha
Li, Wei
Jilaihawi, Hasan
Piayda, Kerstin
Sievert, Horst
Zhou, Daxin
Pan, Wenzhi
Ge, Junbo
author_sort Zhang, Xiaochun
collection PubMed
description ReAces is a novel puncturable transcatheter atrial septal defect occluder. The device success rate was 100% (n = 14 of 14) in the animal experiment. Four swine successfully received puncture of the device 60 days after implantation of the device. The acute procedure success rate in the 10 patients was 100%. Transthoracic echocardiography examination showed that the devices were well positioned with no residual shunt, and the area of central portion of occluder was substantially thin. It is safe and effective to use ReAces for closure of secundum atrial septal defect, and puncture the atrial septum at the portion of the device is feasible.
format Online
Article
Text
id pubmed-9831856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98318562023-01-12 A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study Zhang, Xiaochun Chen, Shasha Li, Wei Jilaihawi, Hasan Piayda, Kerstin Sievert, Horst Zhou, Daxin Pan, Wenzhi Ge, Junbo JACC Basic Transl Sci Original Research - Clinical ReAces is a novel puncturable transcatheter atrial septal defect occluder. The device success rate was 100% (n = 14 of 14) in the animal experiment. Four swine successfully received puncture of the device 60 days after implantation of the device. The acute procedure success rate in the 10 patients was 100%. Transthoracic echocardiography examination showed that the devices were well positioned with no residual shunt, and the area of central portion of occluder was substantially thin. It is safe and effective to use ReAces for closure of secundum atrial septal defect, and puncture the atrial septum at the portion of the device is feasible. Elsevier 2022-10-26 /pmc/articles/PMC9831856/ /pubmed/36644281 http://dx.doi.org/10.1016/j.jacbts.2022.06.010 Text en © 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research - Clinical
Zhang, Xiaochun
Chen, Shasha
Li, Wei
Jilaihawi, Hasan
Piayda, Kerstin
Sievert, Horst
Zhou, Daxin
Pan, Wenzhi
Ge, Junbo
A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title_full A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title_fullStr A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title_full_unstemmed A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title_short A Novel Puncturable Atrial Septal Defect Occluder: The Results of Preclinical Experiment and First-in-Human Study
title_sort novel puncturable atrial septal defect occluder: the results of preclinical experiment and first-in-human study
topic Original Research - Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831856/
https://www.ncbi.nlm.nih.gov/pubmed/36644281
http://dx.doi.org/10.1016/j.jacbts.2022.06.010
work_keys_str_mv AT zhangxiaochun anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT chenshasha anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT liwei anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT jilaihawihasan anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT piaydakerstin anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT sieverthorst anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT zhoudaxin anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT panwenzhi anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT gejunbo anovelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT zhangxiaochun novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT chenshasha novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT liwei novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT jilaihawihasan novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT piaydakerstin novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT sieverthorst novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT zhoudaxin novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT panwenzhi novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy
AT gejunbo novelpuncturableatrialseptaldefectoccludertheresultsofpreclinicalexperimentandfirstinhumanstudy

Ejemplares similares